18:04 , Aug 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Thrombocytopenia Mouse studies suggest depleting NK cells or inhibiting NK cell activation could help treat fetal/neonatal alloimmune thrombocytopenia (FNAIT). In a mouse model of FNAIT, a tool antibody that depletes NK cells decreased uterine NK...
07:00 , Jun 23, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Endothelial cell nitric oxide synthase 3 (NOS3; eNOS)

Genitourinary disease INDICATION: Genitourinary Patient sample and mouse studies suggest promoting NOS3 activity with Viagra sildenafil could help prevent preeclampsia. In patient placental tissue samples or vascular endothelium from a mouse model of preeclampsia, markers of NOS3...
07:00 , Mar 31, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: E. coli DNA adenine methyltransferase (Dam)

Infectious disease INDICATION: Bacterial infection Cell studies suggest inhibiting E. coli Dam could help enhance the sensitivity of the bacterial infection to antibiotics. In a cultured strain of E. coli, knockout of Dam plus an antibiotic -...
07:00 , Jul 17, 2014 |  BC Innovations  |  Targets & Mechanisms

New route for old cancer agents

Researchers at the University of Wisconsin-Madison and Cellectar Biosciences Inc. have exploited differences in lipid architecture between cancer and normal cells to create compounds that deliver radiolabels selectively to different types of malignant cells while...
08:00 , Jan 9, 2014 |  BC Innovations  |  Cover Story

Light it up

Poor tumor definition is a central challenge in cancer surgery, which aims to remove all malignant cells while preserving normal tissue. Now, a team from The University of Texas Southwestern Medical Center has designed fluorescent...
08:00 , Jan 5, 2012 |  BC Innovations  |  Tools & Techniques

Eau de fluorescence

Researchers from the National Cancer Institute and The University of Tokyo have developed a topical fluorescent probe that they have shown can detect residual tumor cells in mice during cancer surgery.1 The researchers will next...
08:00 , Nov 2, 2009 |  BioCentury  |  Strategy

An acquirer's golden rule

Peer Schatz, CEO of Qiagen N.V., says he's not a fan of building companies through acquisition. But since he took over the helm in 2004, the sample and assay technologies company has been one of...
07:00 , Sep 29, 2008 |  BioCentury  |  Product Development

The eyes have it

Continued increases in investment, new targets and expanded delivery options signal growing interest in ophthalmics, resulting in nearly 40 deals since January 2007, led by Novartis AG's $10.4 billion purchase of a 25% stake in...
07:00 , Aug 7, 2006 |  BioCentury  |  Finance

Ebb & Flow

Last week saw a trio of relatively fresh faces raise a total of more than $140 million in series B rounds. Although Acceleron, Esprit and Biodel have divergent strategies and play in different indications, their...
08:00 , Feb 14, 2005 |  BioCentury  |  Politics, Policy & Law

Cracking the SBIR dam

The biotech industry soon will have a chance to persuade lawmakers to overturn the Small Business Administration's policy of denying Small Business Innovation Research awards to companies that are majority-owned by venture capital firms. The...